TNF and inflammatory bowel disease: To the authors’ knowledge, these data are the first to demonstrate that over half of the patients with IBD in China who were prescribed anti-TNF therapy as their first-line biologic therapy are at risk of experiencing suboptimal response at 2 years of anti-TNF initiation.